LUCIUS 卢修斯 达克替尼 Dacomitinib细胞肺癌

达克替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Dacomitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

Each film-coated tablet contains

细胞肺癌

Dacomitinib ....
Indication:

LUCiUS

LuciDac is a kinase inhibitor indicated for

PHARMACEUTICALS

the first-line treatment of patients with
metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor

Rx Only

receptor (EGFR) exon 19 deletion or exon
21 L858R substitution mutations as detected

LuciDac

by an FDA-approved test
Dosage and Use:
Recommended Dosage: 45 mg orally onc
daily with or without food.

Dacomitinib Tablets

FDA批准

torage: in a dry place and store at 20C to

Warning

15mg

Keep medicine out of reach of Children. Do
not administer LuciDac during Pregnancy
and Lactation.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by:

LUCIUS

权威认证

Thongmang village. Xaythany district,
Vientiane Capital, Laos
www.luctus.la

warning : To be sold hu retail on wosse ou
o feestered physicians only, and as directe
le paysician

30 Tablets

口碑质量

适应症:
适用于一线治疗经FDA批准的检测方法检测为表皮生长
因子受体(EGFR)外显子19缺失或外显子21L858R替代

突变的转移性非小细胞肺癌(NSCLC)的患者。
推荐剂量:
1、每日口服一次,每次45mg,直至疾病进展或出现不可
接受的毒性。
2、随餐或空腹均可。